Exploiting the potential of molecular profiling in Parkinsons disease: Current practice and future probabilities

Expert Review of Molecular Diagnostics

Volumn 10, Issue 8, 2010, Pages 1035-1050

  Mellick, George D ^a,b,c   Silburn, Peter A ^c,d   Sutherland, Greg T ^a   Siebert, Gerhard A ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

biomarkers; genomic; metabolomic; molecular profiling; Parkinsons disease; proteomic; transcriptomic

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTOME;

CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; GENE EXPRESSION PROFILING; GENETIC LINKAGE; HUMAN; LEWY BODY; METABOLOMICS; MOLECULAR GENETICS; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROGNOSIS; PROTEOMICS; REVIEW;

BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; GENE EXPRESSION PROFILING; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LEWY BODIES; METABOLOMICS; MICROARRAY ANALYSIS; OLFACTORY PERCEPTION; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PROTEOMICS;

EID: 78649231863     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.86     Document Type: Review

References (137)

1. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 48(5), 1277-1281 (1997).
2. Peters CM, Gartner CE, Silburn PA, Mellick GD. Prevalence of Parkinson's disease in metropolitan and rural Queensland: a general practice survey. J. Clin. Neurosci. 13(3), 343-348 (2006).
3. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63(7), 1240-1244 (2004).
4. Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5), 384-386 (2007).
5. Findley LJ. The economic impact of Parkinson's disease. Parkinsonism Relat. Disord. 13 (Suppl.), S8-S12 (2007).
6. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov. Disord. 20(11), 1449-1454 (2005).
7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2), 197-211 (2003).
8. Cookson MR, Hardy J, Lewis PA. Genetic neuropathology of Parkinson's disease. Int. J. Clin. Exp. Pathol. 1(3), 217-231 (2008).
9. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57(8), 1497-1499 (2001).
10. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56(1), 33-39 (1999).
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases [see comments]. J. Neurol. Neurosurg. Psychiatry 55(3), 181-184 (1992).
12. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (Pt 4), 861-870 (2002).
13. Sander C. Genomic medicine and the future of health care. Science 287(5460), 1977-1978 (2000).
14. De Gruttola VG, Clax P, DeMets DL et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health Workshop. Control. Clin. Trials 22(5), 485-502 (2001).
15. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8), 1237-1244 (1988).
16. Haehner A, Boesveldt S, Berendse HW et al. Prevalence of smell loss in Parkinson's disease - a multicenter study. Parkinsonism Relat. Disord. 15(7), 490-494 (2009).
17. Haehner A, Hummel T, Reichmann H. Olfactory dysfunction as a diagnostic marker for Parkinson's disease. Expert Rev. Neurother. 9(12), 1773-1779 (2009).
18. Hawkes C. Olfaction in neurodegenerative disorder. Adv. Otorhinolaryngol. 63, 133-151 (2006).
19. Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M. Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci. Ther. 15(2), 157-182 (2009).
20. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7), 968-975 (2006).
21. Lees AJ. The Parkinson chimera. Neurology 72 (7 Suppl.), S2-S11 (2009).
22. Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes - an algorithm for clinicians to "PARK" genes and beyond. Mov. Disord. 24(14), 2042-2058 (2009).
23. Mehta SH, Morgan JC, Sethi KD. Neuroimaging and transcranial ultrasonography in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 8(4), 297-303 (2008).
24. Berg D, Becker G, Zeiler B et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53(5), 1026-1031 (1999).
25. Berg D, Behnke S, Walter U. Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall. Med. 27(1), 12-19 (2006).
26. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 7(11), 1044-1055 (2008).
27. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J. Auton. Nerv. Syst. 53 (2-3), 230-234 (1995).
28. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76(2), 249-251 (2005).
29. 123I-MIBG uptake reflects cardiac sympathetic dysfunction in Lewy body disease. Neurology 69(14), 1460-1465 (2007).
30. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov. Disord. 24 (Suppl. 2), S732-S741 (2009).
31. Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr. Neurol. Neurosci. Rep. 6(4), 295-301 (2006).
32. Siderowf A, Stern MB. Premotor Parkinsons disease: clinical features, detection, and prospects for treatment. Ann. Neurol. 64 (Suppl. 2), S139-S147 (2008).
33. Stern MB. The preclinical detection of Parkinsons disease: ready for prime time? Ann. Neurol. 56(2), 169-171 (2004).
34. Poewe W, Scherfler C, Tolosa E, Marek K. Supplement neuroimaging movement disorders. Mov. Disord. 24 (Suppl. 2), S655 (2009). • A 'must read' for those interested in the potential of imaging biomarkers for Parkinson's disease (PD) and the identification of the prodrome of this disorder.
35. Belin AC, Westerlund M. Parkinsons disease: a genetic perspective. FEBS J. 275(7), 1377-1383 (2008).
36. Klein C. Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch. Neurol. 63(3), 328-334 (2006).
37. Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol. 2(3), 136-146 (2006).
38. Paulson HL. Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations. Neurol. Clin. 20(3), 627-643, v (2002).
39. McInerney-Leo A. Genetic testing in Parkinsons disease. Mov. Disord. 20(7), 908-909 (2005). • Presents a very thoughtful discussion of the important considerations involved with genetic testing for PD. Although over 5 years old, the important issues raised remain extremely relevant.
40. Harbo HF, Finsterer J, Baets J et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur. J. Neurol. 16(7), 777-785 (2009).
41. Scherzer CR. Chipping away at diagnostics for neurodegenerative diseases. Neurobiol. Dis. 35(2), 148-156 (2009).
42. Hennecke G, Scherzer CR. RNA biomarkers of Parkinson's disease: developing tools for novel therapies. Biomark. Med. 2(1), 41-53 (2008).
43. Schadt EE, Lamb J, Yang X et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat. Genet. 37(7), 710-717 (2005).
44. Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann. Neurol. 64 (Suppl. 2), S111-S121 (2008). •• Articulates the important requirements for the discovery of effective biomarkers with an emphasis on PD.
45. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med. 147(3), 126-132 (2006).
46. Mohr S, Liew CC. The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol. Med. 13(10), 422-432 (2007).
47. Seyfert S, Kunzmann V, Schwertfeger N, Koch HC, Faulstich A. Determinants of lumbar CSF protein concentration. J. Neurol. 249(8), 1021-1026 (2002).
48. Hong Z, Shi M, Chung KA et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133 (Pt 3), 713-726 (2010).
49. Soldner F, Hockemeyer D, Beard C et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5), 964-977 (2009).
50. Matigian N, Abrahamsen G, Sutharsan R et al. Disease-specific, neurosphere-derived cells as models for brain disorders. Dis. Model. Mech. DOI: 10.1242/dmm.005447 (2010) (Epub ahead of print).
51. Lederberg J, McCray A. 'Ome sweet 'omics - a genealogical treasury of words. The Scientist 15(7), 8(2001).
52. Pankratz N, Foroud T. Genetics of Parkinson disease. Genet. Med. 9(12), 801-811 (2007).
53. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 31(7), 763-780 (2010).
54. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med. 11, e22 (2009).
55. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics of Parkinson's syndromes: a critical review. Curr. Opin. Genet. Devel. 19(3), 254-265 (2009).
56. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18 (R1), R48-R59 (2009).
57. Nichols WC, Kissell DK, Pankratz N et al. Variation in GIGYF2 is not associated with Parkinson disease. Neurology 72(22), 1886-1892 (2009).
58. Kruger R, Sharma M, Riess O et al. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol. Aging DOI: 10.1016/j. neurobiolaging.2009.11.021 (2009) (Epub ahead of print).
59. Prestel J, Sharma M, Leitner P et al. PARK11 is not linked with Parkinson's disease in European families. Eur. J. Hum. Genet. 13(2), 193-197 (2005).
60. Wirdefeldt K, Burgess CE, Westerberg L, Payami H, Schalling M. A linkage study of candidate loci in familial Parkinson's disease. BMC Neurol. 3, 6(2003).
61. Fung HC, Scholz S, Matarin M et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 5(11), 911-916 (2006).
62. Maraganore DM, de Andrade M, Lesnick TG et al. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77(5), 685-693 (2005).
63. Elbaz A, Nelson LM, Payami H et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol. 5(11), 917-923 (2006).
64. Evangelou E, Maraganore DM, Annesi G et al. Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153 B (1), 220-228 (2009).
65. Latourelle JC, Pankratz N, Dumitriu A et al. Genomewide association study for onset age in Parkinson disease. BMC Med. Genet. 10, 98(2009).
66. Pankratz N, Wilk JB, Latourelle JC et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet. 124(6), 593-605 (2009).
67. Satake W, Nakabayashi Y, Mizuta I et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41(12), 1303-1307 (2009).
68. Simon-Sanchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41(12), 1308-1312 (2009).
69. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA 103(15), 5923-5928 (2006).
70. Marshall E. Getting the noise out of gene arrays. Science 306(5696), 630-631 (2004).
71. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365(9458), 488-492 (2005).
72. Amino T, Uchihara T, Tsunekawa H et al. Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction. Neurosci. Res. 60(3), 314-318 (2008).
73. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9(3), 293-348 (2006).
74. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 11(8), 493-498 (2005).
75. Sutherland GT, Matigian NA, Chalk AM et al. A cross-study transcriptional analysis of Parkinson's disease. PloS ONE 4(3), e4955 (2009). •• Provides an extensive re-examination of the important trans crip tomic studies in PD and shows that data concordance can be improved when a systematic analytical approach is used. It also shows that pathway analyses reveal superior consistency between studies compared with published gene lists. It also clearly demonstrates how trans crip tomics can mark pathological changes in tissue samples.
76. Scherzer CR, Grass JA, Liao Z et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein. Proc. Natl Acad. Sci. USA 105(31), 10907-10912 (2008).
77. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B et al. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol. Dis. 26(3), 606-614 (2007).
78. Simunovic F, Yi M, Wang Y et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 132 (Pt 7), 1795-1809 (2009).
79. Salmi J, Nyman TA, Nevalainen OS, Aittokallio T. Filtering strategies for improving protein identification in high-throughput MS/MS studies. Proteomics 9(4), 848-860 (2009).
80. Dunn MJ. PROTEOMICS Reviews 2009. Proteomics 9(4), 804-807 (2009). • Readers interested in the advances in proteomics are directed to this issue of Proteomics, which contains review articles covering the latest in technology, bioinformatics and animal proteomics methods.
81. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4(12), 3943-3952 (2004). • The only comprehensive human brain proteomic analysis published to date comparing PD and control substantia nigra.
82. Pan S, Rush J, Peskind ER et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res. 7(2), 720-730 (2008).
83. Xia Q, Liao L, Cheng D et al. Proteomic identification of novel proteins associated with Lewy bodies. Front. Biosci. 13, 3850-3856 (2008).
84. Pienaar IS, Dexter DT, Burkhard PR. Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis. Expert Rev. Proteomics 7(2), 205-226 (2010).
85. Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129(4), 526-529 (2008).
86. Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7(2), 125-133; discussion 173-180 (2005).
87. Sinha A, Srivastava N, Singh S et al. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach. Clin. Chim. Acta 400 (1-2), 14-20 (2009).
88. Goldknopf IL, Bryson JK, Strelets I et al. Abnormal serum concentrations of proteins in Parkinson's disease. Biochem. Biophys. Res. Commun. 389(2), 321-327 (2009). • Important blood proteomic study that identifed 21 candidate proteins contributing to optimal discrimination between PD and control groups.
89. Bogdanov M, Matson WR, Wang L et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131 (Pt 2), 389-396 (2008). •• Blood plasma metabolomic profiling study that shows promise for the identification of discriminators between PD and control subjects. This approach has been followedup in individuals from families carrying PD-related LRR2 mutations [103].
90. Dufek M, Hamanova M, Lokaj J et al. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat. Disord. 15(4), 318-320 (2009).
91. Schwarzschild MA, Schwid SR, Marek K et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65(6), 716-723 (2008).
92. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166(5), 561-567 (2007).
93. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 167(1), 90-95 (2008).
94. Bharucha KJ, Friedman JK, Vincent AS, Ross ED. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J. Neurol. 255(12), 1957-1962 (2008).
95. Lu M, Faull KF, Whitelegge JP et al. Proteomics and mass spectrometry for cancer biomarker discovery. Biomark. Insights 2, 347-360 (2007).
96. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol. 16(9), 373-378 (1998).
97. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35(2), 165-176 (2009).
98. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 22(5), 245-252 (2004).
99. 1H-NMR-based metabonomics. Nat. Med. 8(12), 1439-1444 (2002).
100. Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34(1), 173-186 (2009).
101. Shi H, Vigneau-Callahan KE, Matson WR, Kristal BS. Attention to relative response across sequential electrodes improves quantitation of coulometric array. Anal. Biochem. 302(2), 239-245 (2002).
102. Vigneau-Callahan KE, Shestopalov AI, Milbury PE, Matson WR, Kristal BS. Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats. J. Nutr. 131(3), 924S-932S (2001).
103. Johansen KK, Wang L, Aasly JO et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PloS ONE 4(10), e7551 (2009).
104. Ahmed SS, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 16(1), 63(2009).
105. Andreadou E, Nikolaou C, Gournaras F et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 111(9), 724-728 (2009).
106. Ascherio A, LeWitt PA, Xu K et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66(12), 1460-1468 (2009).
107. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther. 324(1), 1-7 (2008).
108. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4(4), 309-314 (2004). •• A must read for people interested in biomarker discovery. It provides an excellent discussion on rules of evidence and result validation in discovery science.
109. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann. Intern. Med. 138(8), 644-650 (2003).
110. Geschwind DH, Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature 461(7266), 908-915 (2009).
111. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057), 376-380 (2005).
112. Shendure J, Porreca GJ, Reppas NB et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309(5741), 1728-1732 (2005).
113. Eid J, Fehr A, Gray J et al. Real-time DNA sequencing from single polymerase molecules. Science 323(5910), 133-138 (2009).
114. Marder KS, Tang MX, Mejia-Santana H et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch. Neurol. 67(6), 731-738 (2010).
115. Ibanez P, Lesage S, Janin S et al. α-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch. Neurol. 66(1), 102-108 (2009).
116. Singleton AB, Farrer M, Johnson J et al. α-synuclein locus triplication causes Parkinson's disease. Science 302(5646), 841(2003).
117. Voutsinas GE, Stavrou EF, Karousos G et al. Allelic imbalance of expression and epigenetic regulation within the α-synuclein wild-type and p. Ala53Thr alleles in Parkinson disease. Hum. Mutat. 31(6), 685-691 (2010).
118. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J. Neuropathol. Exp. Neurol. 68(8), 880-891 (2009).
119. Graeber MB. Biomarkers for Parkinson's disease. Exp. Neurol. 216(2), 249-253 (2009).
120. Myers AJ, Gibbs JR, Webster JA et al. A survey of genetic human cortical gene expression. Nat. Genet. 39(12), 1494-1499 (2007).
121. Hovatta I, Zapala MA, Broide RS et al. DNA variation and brain region-specific expression profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. Genome Biol. 8(2), R25 (2007).
122. Hauser MA, Li YJ, Takeuchi S et al. Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum. Mol. Genet. 12(6), 671-677 (2003).
123. Lesnick TG, Papapetropoulos S, Mash DC et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet. 3(6), e98 (2007).
124. Noureddine MA, Li YJ, van der Walt JM et al. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov. Disord. 20(10), 1299-1309 (2005).
125. Liang X, Slifer M, Martin ER et al. Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10. Hum. Mutat. 30(3), 463-471 (2009).
126. Webster JA, Gibbs JR, Clarke J et al. Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet. 84(4), 445-458 (2009).
127. Elstner M, Morris CM, Heim K et al. Single-cell expression profiling of dopaminergic neurons combined with association analysis identifes pyridoxal kinase as Parkinson's disease gene. Ann. Neurol. 66(6), 792-798 (2009).
128. Scholz B, Svensson M, Alm H et al. Striatal proteomic analysis suggests that first L-DOPA dose equates to chronic exposure. PloS ONE 3(2), e1589 (2008).
129. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice - a model of familial Parkinson's disease. Neurobiol. Dis. 18(3), 492-498 (2005).
130. Van Laar VS, Dukes AA, Cascio M, Hastings TG. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 29(3), 477-489 (2008).
131. Smith DJ. Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics. J. Bioenerg. Biomembr. 41(6), 487-491 (2009).
132. Kim ST, Moon W, Chae Y, Kim YJ, Lee H, Park HJ. The effect of electro acupuncture for 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced proteomic changes in the mouse striatum. J. Physiol. Sci. 60(1), 27-34 (2010).
133. Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MB. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. J. Neural. Transm. 116(11), 1457-1472 (2009).
134. Ichibangase T, Saimaru H, Takamura N et al. Proteomics of Caenorhabditis elegans over-expressing human α-synuclein analyzed by fluorogenic derivatizationliquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. Biomed. Chromatogr. 22(3), 232-234 (2008).
135. Park J, Kim Y, Chung J. Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila. Dis. Model. Mech. 2 (7-8), 336-340 (2009).
136. Scherzer CR, Jensen RV, Gullans SR, Feany MB. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum. Mol. Genet. 12(19), 2457-2466 (2003).
137. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 66(5), 646-661 (2010).